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Background
UK Biobank is a well-characterised cohort of over 500 000 parti-
cipants including genetics, environmental data and imaging. An
online mental health questionnaire was designed for UK Biobank
participants to expand its potential.
Aims
Describe the development, implementation and results of this
questionnaire.
Method
An expert working group designed the questionnaire, using
established measures where possible, and consulting a patient
group. Operational criteria were agreed for defining likely
disorder and risk states, including lifetime depression, mania/
hypomania, generalised anxiety disorder, unusual experiences
and self-harm, and current post-traumatic stress and hazardous/
harmful alcohol use.
Results
A total of 157 366 completed online questionnaires were avail-
able by August 2017. Participants were aged 45–82 (53% were
≥65 years) and 57% women. Comparison of self-reported diag-
nosed mental disorder with a contemporary study shows a
similar prevalence, despite respondents being of higher average
socioeconomic status. Lifetime depression was a common
finding, with 24% (37 434) of participants meeting criteria and
current hazardous/harmful alcohol use criteria were met by 21%
(32 602), whereas other criteria were met by less than 8% of the
participants. There was extensive comorbidity among the syn-
dromes. Mental disorders were associated with a high neuroti-
cism score, adverse life events and long-term illness; addiction
and bipolar affective disorder in particular were associated with
measures of deprivation.
Conclusions
The UK Biobank questionnaire represents a very large mental
health survey in itself, and the results presented here show high
face validity, although caution is needed because of selection
bias. Built into UK Biobank, these data intersect with other health
data to offer unparalleled potential for crosscutting biomedical
research involving mental health.
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UK Biobank
UK Biobank is a very large, population-based cohort study estab-
lished to identify the determinants of common life-threatening
and disabling conditions.1 Most of these conditions, such as heart
disease, stroke and mental disorders, are multifactorial, involving
multiple genes of small effect, and complex relationships with envir-
onmental exposures. This means large samples are required to study
associations between these exposures and disease, and to identify
targets for treatment and prevention.2 The utility of traditional epi-
demiological study designs are often limited by their focus on single
disorders or exposures and relatively modest sample sizes.3 UK
Biobank is an open-access resource providing detailed characterisa-
tion of over half a million people aged 40–69 years at recruitment,
with proposed long-term follow-up. Recruitment was completed
in 2010, along with consent for future contact and linkage to rou-
tinely collected health-related data, such as those produced by the
National Health Service (NHS). Baseline measures were extensive,
from family history to sensory acuity (a searchable breakdown is
available at www.ukbiobank.ac.uk), and the resource continues to
grow. In 2017 genotyping of the whole cohort was complete, a
range of blood biomarkers were released in 2019, and multimodal
imaging is underway for 100 000 participants.4 Locality environ-
mental factors, such as air pollution, are also available. The design
of UK Biobank offers the opportunity to examine a wide range of
* This paper is a reanalysis of data previously published in a paper –
Davis KAS, Coleman JRI, et al. Mental health in UK Biobank, 2018
(https://doi.org/10.1192/bjo.2018.12; corrections: https://doi.org/10.
1192/bjo.2018.19 and https://doi.org/10.1192/bjo.2018.47) that was
retracted on 17 June 2019 (https://doi.org/10.1192/bjo.2019.46) for
reasons of accuracy in the reporting of alcohol use disorders, as dis-
cussed in an editorial – Kaufman KR, Malhi GS, Bhui KS. When a corri-
gendum is not sufficient, 2019 (https://doi.org/10.1192/bjo.2019.41).
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risk factors and outcomes in a sample that has the size to provide the
power to detect small effects, making UK Biobank a highly efficient
resource for observational epidemiology.
The impact of mental disorders on disability and quality of life is
considerable,5 accounting for the equivalent of over 1.2 million
person-years lost to disability frommental and substance-use disor-
ders in England alone in 2013.6 The detrimental impact of mental
disorders both on physical disease onset and outcomes7–9 is particu-
larly notable for this project. The UK Biobank baseline data collec-
tion of mental health, consisted of several questions about mood
and a neuroticism scale, expanded for the last 172 729 recruited par-
ticipants with questions to allow provisional categorisation of mood
disorder;10 however, there was considerable scope for further char-
acterisation of mental disorders among participants. The availability
of mental health phenotypes in conjunction with the wealth of other
data in the UK Biobank offers considerable opportunities to study
aetiological and prognostic factors, particularly the interplay
between factors that have usually been in separate research
domains.4
Outcome ascertainment
Characterising mental disorders in a cohort such as UK Biobank
poses challenges. First, most mental disorders manifest before age
30 years and have fluctuating courses,11 so a ‘snapshot’ of disorder
status at one point in time, as identified by most screening tools, is
likely to be less useful than a ‘lifetime’ history – although ‘lifetime’
instruments suffer more from measurement error such as recall
bias.12,13 Second, traditional diagnostic approaches to mental disor-
ders, relying upon clinician assessment at interview, would be pro-
hibitively expensive in a cohort of this size. Third, using self-report
of diagnosis or data from record linkages relies upon recognition of
illness and reflects healthcare usage patterns, whereas many people
with mental disorders never seek or receive treatment.11,14 In
response to these challenges, we developed a dual approach: second-
ary care record linkage for identification of more severe illnesses
such as schizophrenia15 and self-report of symptoms of common
mental disorder, which might not have come to clinical attention.
As part of our mental health phenotyping programme we therefore
developed an online mental health questionnaire (MHQ) for
participants to complete regarding lifetime symptoms of mental dis-
orders. TheMHQ aimed to exploit the efficiency of ‘e-surveys’16 and
provide the detail needed to identify mental health disorders
without the need for a clinical assessment.
Aims
The present paper aims to describe the development, implementa-
tion and results of the MHQ. We provide descriptive data on the
numbers of UK Biobank participants meeting diagnostic criteria
for specific disorders and on the frequency of exposure to risk
factors. We also evaluate the likely representativeness of respon-
dents by comparing respondent sociodemographic characteristics
to that of the UK population using census data and comparing
self-reported mental disorder diagnosis with the Health Survey for
England (HSE) data.17 This will assist researchers considering or
undertaking epidemiological research to evaluate the potential
strengths and weaknesses of using UK Biobank data to look at
mental health.
Method
Questionnaire development
A mental health research reference group formed of approximately
50 individuals (see supplementary Appendix 1 available at https://
doi.org/10.1192/bjo.2019.100) participated in discussions about a
strategy for mental health phenotyping in UK Biobank, including
a workshop in January 2015. From this, a smaller steering group
was established and led the development of the MHQ. The group
recommended that the MHQ should concentrate on depression,
as it was likely to represent the greatest burden in the cohort, with
some questions about other common disorders, including anxiety,
alcohol misuse and addiction, plus risk factors for mental disorders
not captured at participants’ baseline assessment.
The intention was to create a composite questionnaire out of
previously existing and validated measures, taking into account
participant acceptability (time, ease of use and ensuring questions
were unlikely to offend), scope for collaborations with international
studies (for example the Psychiatric Genomics Consortium)
through making results comparable, and the need to balance
depth and breadth of phenotyping. The base of the questionnaire
was the measurement of lifetime depressive disorder using the
Composite International Diagnostic Interview Short Form (CIDI-
SF),18 modified to provide lifetime history, as used to identify
cases and controls for some existing studies in the Psychiatric
Genomics Consortium.19 The CIDI-SF uses a branching structure
with screening questions and skip rules to limit detailed questions
to the relevant areas for each participant. Other measures were
then added to this, as summarised in supplementary Table SM1.
Where the group were unable to find existing measures that fulfilled
these criteria, questions were written or adapted, as indicated in
supplementary Table SM1. These sections have not been externally
validated, but the questions along with the full questionnaire can be
seen on the UK Biobank website (http://biobank.ctsu.ox.ac.uk/
crystal/refer.cgi?id=22), for researchers to evaluate.
Testing and ethical approval
The use of branching questions in the MHQ means that those with
established and multiple mental disorders have a longer, more
detailed, questionnaire. To improve acceptability in this group, we
worked with a patient advisory group at the National Institute of
Health Research (NIHR) Biomedical Research Centre at the South
London and Maudsley NHS Foundation Trust in designing the
questionnaire and invitation.20 We then piloted the questionnaire
for functionality (for example ease of completion) among an
online cohort of 14 836 volunteers aged over 50 and living in the
UK, who completed the questionnaire as part of signing up to
take part in the Platform for Research Online to investigate
Genetics and Cognition in Ageing (PROTECT).21 Of those who
started the questionnaire 98.8% completed it, taking a median
time of 15 min. Some PROTECT participants commented that
they wanted the opportunity to explain why they felt they had
experienced symptoms of depression. In response to this, we
added a question to the depression section on loss or bereavement,
and a free-text box – neither were designed to change diagnostic
algorithms, but may add to future analyses.
The questionnaire was approved as a substantial amendment to
UK Biobank approval from the North West - Haydock Research
Ethics Committee, 11/NW/0382. Participation in the UK Biobank
is voluntary, and participants are free to withdraw at any time.
Informed written consent was obtained by participants at baseline.
Online questionnaires such as the MHQ are voluntary.
Administration to UK Biobank participants
We incorporated the final MHQ into the UK Biobank web-ques-
tionnaire platform and presented it to participants as an online
questionnaire entitled ‘thoughts and feelings’. To participants who
had agreed to email contact (339 092/503 328 participants, 67%)
we sent a hyperlink to their personalised questionnaire. The
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invitation explained the importance of collecting further informa-
tion about mental health and emphasised that UK Biobank was
unable to respond to concerns raised by the participant in the ques-
tionnaire, instead directing them to several sources of potential
support. Participants could skip questions they preferred not to
answer, and they could save answers to return to the questionnaire
later. We sent reminder emails at 2 weeks and 4 months to those
who had not started or had partially completed the questionnaire.
The MHQ will continue to be available on the participant area of
the UK Biobank website, and since 2017 the annual postal newslet-
ter contains an invitation to log on to the participant area and
complete questionnaires, which will reach those for whom no
email contact was possible. Data from the MHQ will therefore
continue to accrue. The current numbers and aggregate data can
be accessed from the public data showcase (http://biobank.ctsu.ox.
ac.uk/crystal/label.cgi?id=136). More detail on the rollout and asso-
ciated communications can be found on the UK Biobank website
(http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=22).
Defining outcomes from the MHQ
Some suggested case definitions for the evaluation of the responses
on the MHQ are detailed in supplementary Appendix 2. They arose
either from the instruments used in the MHQ or by consensus cri-
teria agreed by the working committee who wrote the MHQ.
Diagnostic criteria were evaluated for depression (major depressive
disorder), hypomania or mania, generalised anxiety disorder
(GAD), hazardous/harmful alcohol use (alcohol use disorder) and
post-traumatic stress disorder (PTSD). Addiction to substances
and/or behaviour was defined based on self-report alone. Unusual
experiences (describing potential symptoms of psychosis) and
self-harm were also defined as phenomena that are important for
phenotyping, but are not specific to any disorder. We combined
outcomes to divide the cohort into five mood disorder groups, as
shown in supplementary Fig. MD1.
Fulfilling the diagnostic criteria based on a self-report question-
naire does not allow us to rule out other psychiatric disorders,
psychological or situational factors that might better explain the
symptoms, which may have been elicited had there been a clinical
evaluation. Therefore, we would regard any case classification
arising from theMHQas ‘likely’, rather than a confirmed psychiatric
disorder. The issue becomes particularly problematic for disorders
that are less common in the population, such as bipolar affective dis-
order, where literature shows that using questionnaires to screen the
population may overestimate prevalence.22 Therefore, although we
report the presence of hypomania/mania symptoms for the whole
population, we onlymake the likely diagnosis of bipolar affective dis-
order in people with a history of depression, a subpopulation where
the prevalence of bipolar affective disorder is higher, and therefore
screening questionnaires have better positive predictive values.23
Analysis and data sharing
Data were supplied by UK Biobank on 8 August 2017 under appli-
cation number 16577. This data is open-access subject to the usual
access procedures (www.ukbiobank.ac.uk).
Formal operational criteria (supplementary Appendix 2) were
written by K.A.S.D. based on consensus within the consortium
(see Defining cases from the MHQ, above), with checks by J.R.I.C.,
G.B. and M.H. (whole) and C.D., N.G., W.L. and D.J.S. (mood
disorders section). R code for analysis was developed by J.R.I.C.,
with the code posted for comments during development, trialled
on pilot data and checked by K.A.S.D. and G.B. Portions of the
data were analysed independently in parallel by other groups and
subsequently compared (for example for mood disorders, by N.
G./B.C.). The R code is freely available from Mendeley Data for
the purpose of reproducing these analyses or developing further
analyses (https://data.mendeley.com/datasets/kv677c2th4/3). We
used R version 3.4.0–3.5.1 and MS Excel for analyses. We report
numbers and proportions within the sample and do not attempt to
give population prevalence estimates. Because of this, and the large
sample size (the 95% CIs on all proportions have width of less than
absolute 1%), CIs were thought not to add meaning, and so are not
shown. A STrengthening the Reporting of OBservational studies in
Epidemiology checklist is included in supplementary Appendix 3.
Comparison data
In order to describe the differences in the sample of participants
in UK Biobank to the general population of the UK, Fry et al24
compareUKBiobank datawith census data, whichwe have replicated
and extended. For health-related data, we have used the Health
Survey for England (HSE), which is a face-to-face household survey
carried out every year25 that in 2014 involved around 8000 adult par-
ticipants designed to be representative of the England adult popula-
tion (with weighting in cases where sampling could not achieve
this). Some topics are ‘core’ and are surveyed every year, whereas
others are ‘supplementary’. Mental health appeared in the 2014
survey as a supplementary topic.17
Results
The setting, recruitment and methods of selection of participants in
UK Biobank have been published elsewhere.1,4,10 For the MHQ
study, 339 092 participants were sent an email invitation, and
157 366 (46% of those emailed) fully completed the questionnaire
by July 2017 (available in August 2017) – which means that the
MHQ had 31% coverage of the UK Biobank cohort. The coverage
continues to grow as the questionnaire is still open for participants.
Figure 1 shows the flow chart of UK Biobank participants who com-
pleted the MHQ. The median time for completion was 14 min, and
82% of respondents completed the questionnaire in under 25 min.
Supplementary Table SM2 shows participant characteristics for
all UK Biobank participants and those who completed the MHQ
compared with population-level data for UK residents in the same
age range. The MHQ participants were aged 45–82 years, with
53% aged 65 or over, and 57% were female. They were different
from the whole UK Biobank cohort and the general population by
being better educated (for example 45% hold a degree v. 32% of
all UK Biobank participants v. 23% in the census), of higher socio-
economic status according to job type, and healthier (28% report
long-standing illness or disability v. 32% all UK Biobank partici-
pants v. 37% census), with lower rates of current smoking.
Table 1 shows that 34% of respondents reported they had
received at least one psychiatric diagnosis from a professional at
some time, and 12% had received two or more. Themost commonly
reported diagnosis was depression, followed by ‘anxiety or nerves’.
Data are compared with the population prevalence estimates from
HSE for this age group.17 The comparison shows that the pattern
and prevalence of diagnosis are similar; for example, a depression
diagnosis was self-reported by 21% of individuals in both samples,
eating disorder by around 1% and bipolar-related disorders by
around 0.5%. The definition in the MHQ differed from that in the
HSE for anxiety (the MHQ definition was broader) and addiction
(MHQ did not require professional diagnosis), and the higher
overall prevalence in the UK Biobank MHQ compared with the
HSE (34.3% v. 28.0%) may be a result of those wider definitions.
Table 2 shows that 45% of participants met criteria for one or
more operationally defined syndromes. Of the lifetime disorders,
depression was most common (24% respondents participants),
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then GAD (7%) and hypomania/mania (2%); current hazardous/
harmful alcohol use was met by 21% and current PTSD by 6%.
Lifetime unusual experiences were reported by 5% of respondents
and self-harm by 4%. Supplementary Table SM3 shows that
women and men were approximately equally likely to have a
history of one or more of the defined syndromes (women 44% v.
men 46%), but differed as to which criteria were met: women
were more likely to have a history of depression or anxiety disorder,
whereas men were more likely to meet criteria for a current hazard-
ous/harmful alcohol use (women 14% v. men 30%). Table 2 also
shows the substantial comorbidity of defined syndromes. Notably,
around three-quarters of participants who met criteria for lifetime
anxiety disorder also met criteria for lifetime depression. Also,
although individuals meeting criteria for PTSD had more than a
twofold risk of all of the lifetime syndromes compared with
average, those identified with hazardous/harmful alcohol use had
little extra risk of lifetime syndromes.
In Table 3, people meeting criteria for the lifetime occurrence of
at least one of depression, bipolar disorder, GAD, unusual experi-
ences or self-reported addiction are seen to be more likely than
those without to come from a younger age group, report adverse
life events and have met criteria for loneliness or social isolation.
They are more likely to have smoked cigarettes and/or used canna-
bis, and to have had a ‘longstanding illness’ at baseline (although the
presence of a mental disorder may have been the illness to which the
participants refer in some cases), but all groups were equally likely to
be achieving recommended levels of physical activity. Markers of
deprivation (area-level deprivation and rented housing) are raised
in groups with a history of mental disorders, especially bipolar
affective disorder and addictions.
The supplementarymaterial includes a section onmood disorder,
showing the results of analyses of MHQ participants by likely
disorder categories (supplementary Fig. MD1). Supplementary
Table MD1 shows the features of these groups. The characteristics
of people who meet diagnostic criteria for depression appear to
be shared by those with subthreshold depressive symptoms.
Supplementary Table MD2 shows comorbidity, and demonstrates a
gradient effect in the presence of a non-depression syndrome rising
from 23% in no depression (mainly hazardous/harmful alcohol
use) to 50% in recurrent depression. Supplementary Table MD3
shows that people with a history of depression or bipolar affective
disorder tend to have worse scores for current mental health.
Discussion
Main findings relating to data-collection methods
This paper has described the development, implementation and
principal descriptive findings from the UK Biobank MHQ. The
implementation of this questionnaire demonstrates that a web-
based questionnaire is an acceptable means of collecting mental
health information at low cost and large scale. Although the data-
collection methods might force more limited data acquisition
than conventional interview methods, with associated uncertainties
in true diagnostic categorisation, we suggest that the survey
achieved an acceptable trade-off between depth of phenotypic infor-
mation and scale of sample size. This means that the UK Biobank
MHQ sample can usefully fill a gap between clinical samples with
detailed mental health disorder information but poor generalisabil-
ity (for example, Clinical Records Interactive Search26) and larger
Invited at baseline (n = 8 767 661)
Recruited at baseline (n  = 503 328)
Not sent an email invitation (n  = 164 126)
Did not respond (n  = 182 159)d
Died (n  = 3346)
Do not want to complete questionnaire (n  = 873)
Unknown (n  = 177 928)
Withdrawn (n  = 12)
Sent email invitation (n  = 339 092)
Sent email invitation after 24 July 2017
(n  = 110)c
Primary reason for not receiving emaila
Responded without being sent an email invite (n  = 433)
Died (n  = 14 228)
Withdrawn (n  = 1020)b
No valid email address (n  = 147 828)
Do not wish to receive emails from UK Biobank (n  = 459)
Do not wish to provide further data (n  = 150)
Other reasons (n  = 8)
Response received via participant website
(n  = 433)d
Response received following email invite
(n  = 156 933)d
Primary reason for non response1
Fig. 1 Flow chart of UK Biobank participants from invitation to completion of mental health questionnaire (MHQ).
Invitations were based on National Health Service registration, age and location. Numbers correct for July 2017.
a. Participants could have multiple reasons for not being sent an email, or for not responding. For the purposes of this flow chart, we have identified the most important reason.
b. Withdrawals include participants who requested no further use and no further access, plus requests for no further contact before 11 April 2017 (after which they are included in
other categories).
c. When data was accessed in August 2017, response data was available for invitations sent up to and including 24 July, whereas results were available for response up to 27 July,
with 110 invitations being sent between these dates. d. The discrepancy between this figure and the 157 366 figure in the paper is because of responses between 24 and 27 July from
those who previously had not responded or who had only just been emailed. The survey has remained open, and is accessible for participants without an email invitation, thus will
continue to accrue data.
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cohorts with superficial identification of mental disorder (such as
the baseline UK Biobank cohort or 23andMe27).
TheMHQachieved a participation rate of 31%of the originalUK
Biobank participants and 46% of those emailed. This response rate is
substantially higher than previous UK Biobank questionnaires,
largely owing to the attention paid to ensure the acceptability of
the invitation and questionnaire and the efficient use of reminders.
Main findings from the questionnaire
Those who completed the MHQ appear to be better educated and
have higher socioeconomic status (job title, household income,
home ownership and area-level deprivation) than those recruited
into UK Biobank overall, and the UK population. Despite this, we
found that rates of self-report diagnoses were similar to population
Table 1 Respondent reports of mental health diagnoses by a professional (self-reported without physician diagnosis for addiction) compared with
diagnoses reported in the Health Survey for England (HSE) 2014a
UK Biobank MHQ responses, age 45–82
years (n = 157 366)
HSE, age 45–84 years
(n = 3272)
n % in sample n Prevalence (95% CI)
All psychotic disorders 723 0.5 11 0.3 (0.2–0.6)
Schizophrenia 157 0.1 NR –
Any other type of psychosis or psychotic illness 604 0.4 NR –
Depression 33 424 21.2 679 20.8 (19.4–22.2)
Mania, hypomania, bipolar or manic-depression 837 0.5 13 0.4 (0.2–0.7)
Anxiety, nerves or generalised anxiety disorderb 22 036 14.0 170 5.2 (4.5–6.0)
Panic attacks 8704 5.5 262 8.0 (7.1–9.0)
Agoraphobia 599 0.4 NR –
Social anxiety or social phobia 1962 1.2 NR –
Any other phobia (for example disabling fear of heights or spiders) 2153 1.4 27 0.8 (0.6–1.2)
Obsessive–compulsive disorder 982 0.6 11 0.3 (0.2–0.6)
A personality disorder 385 0.2 13 0.4 (0.2–0.7)
All eating disorders 1851 1.2 26 0.8 (0.5–1.2)
Anorexia nervosa 891 0.6 NR –
Bulimia nervosa 503 0.3 NR –
Psychological overeating or binge-eating 707 0.4 NR –
Autism, Asperger’s or autistic spectrum disorder 223 0.1 NR –
Attention-deficit or attention-deficit hyperactivity disorder 133 0.1 4 0.1 (0–0.3)
Any addiction or dependence 9386 6.0 NR –
Alcohol or drug addictionc 5002 3.2 30 0.9 (0.6–1.3)
Physical alcohol dependence 946 0.6 NA –
Summary
None of above 103 346 65.7 2356 72.0 (70.4–73.5)
≥1 of above 54 020 34.3 916 28.0 (26.5–29.6)
≥2 of above 19 400 12.3 NR –
MHQ, mental health questionnaire; NR, not reported.
a. UK Biobank participants were asked: ‘Have you been diagnosed with one ormore of the followingmental health problems by a professional, even if you don’t have it currently? (tick all that
apply): By professional we mean: any doctor, nurse or person with specialist training (such as a psychologist or therapist). Please include disorders even if you did not need treatment for
them or if you did not agree with the diagnosis’. HSE participants were asked to identify all the mental health conditions they had experienced, then asked whether they had been told by a
doctor, psychiatrist or professional that they had it.
b. HSE participants were asked about generalised anxiety disorder, and not about anxiety and nerves more generically.
c. UK Biobank participants asked: ‘Have you been addicted to or dependent on one or more things, including substances (not cigarettes/coffee) or behaviours (such as gambling)?’ HSE
definition of addiction includes physician diagnosis.
Table 2 Comorbidity between operationally defined syndromesa
Overall
Prevalence, n (%)
(n = 157 366)
Comorbidity, n (%)
Depressionb
Hypomania/
maniac
Anxiety
disorderd
Unusual
experiencese
Self-
harmf
Haz/harm
alcohol useg PTSDh
Total 70 892 (45) 37 434 (24) 2396 (2) 11 111 (7) 7803 (5) 6872 (4) 32 602 (21) 10 064 (6)
Lifetime history
Depressionb 37 434 (24) – 1550 (4) 8444 (23) 3649 (10) 4240 (11) 8156 (22) 6373 (17)
Hypomania/maniac 2396 (2) 1550 (65) – 778 (32) 598 (25) 453 (19) 660 (28) 657 (27)
Anxiety disorderd 11 111 (7) 8444 (76) 778 (7) – 1551 (14) 1704 (15) 2634 (24) 3274 (29)
Unusual experiencese 7803 (5) 3649 (47) 598 (8) 1551 (20) – 1225 (16) 1784 (23) 1594 (20)
Self-harmf 6872 (4) 4240 (62) 453 (7) 1704 (25) 1225 (18) – 1890 (28) 1719 (25)
Current
Hazardous/harmful
alcohol useg
32 602 (21) 8156 (25) 660 (2) 2634 (8) 1784 (5) 1890 (6) – 2572 (8)
PTSDh 10 064 (6) 6373 (63) 657 (7) 3274 (33) 1594 (16) 1719 (17) 2572 (26) –
PTSD, post-traumatic stress disorder.
a. Percentages refer to the proportion of participants with the row syndrome who also have column syndrome. See footnotes b–h, and supplementary Appendix 2 for ‘case’ definitions.
b. Criteria met for major depressive disorder on Composite International Diagnostic Interview Short Form (CIDI-SF) lifetime.
c. Criteria met for hypomania/mania lasting for at least 1 week.
d. Criteria met for generalised anxiety disorder on CIDI-SF lifetime.
e. Reported potential hallucination or delusion at any point in their life.
f. Reported self-harm at some point in their life, asked to report self-harm ‘whether or not you meant to end your life’.
g. Score above cut-off for alcohol use disorder (≥8) on Alcohol Use Disorder Identification Tool during the past year.
h. Criteria met for post-traumatic stress disorder (PTSD) on PTSD Checklist – Short version (PCL-S) in the past month.
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estimates from the HSE. The patterns of association between disor-
ders and demographics were also broadly as predicted by previous
research, which adds to the face validity of the questionnaire. For
example, depression and anxiety were more common in women,
whereas addiction and alcohol misuse were more common in
men, and all disorders were less common in respondents older
than 65 years. The decrease in prevalence of lifetime disorder with
increasing age has been previously noted in cross-sectional
studies, although the causes and implications are not clearly under-
stood.28,29 The high level of hazardous/harmful alcohol (using the
Alcohol Use Disorder Identification Tool) is consistent with the
Adult Psychiatric Morbidity Survey 2014, where they comment
on increased numbers in older age groups since 2007.30
‘Healthy volunteer’ selection bias
The ‘healthy volunteer’ selection bias within the UK Biobank has
been previously explored,24 and further variables influencing par-
ticipation in the MHQ can be predicted and have been found,
such as an interest in mental health and good cognition.31 The
impact of selection biases on disease prevalence are likely to be par-
ticularly strong for mental health disorders, where disorder status or
symptoms may influence participation in research,32,33 and many
risk factors for these disorders, including genetic risk, can be asso-
ciated with non-participation.34 Therefore, the results of the
MHQ should not be used to provide prevalence estimates.
However, the pattern of the measured risk factors among the parti-
cipants with mental disorders in the MHQ, including neuroticism,
trauma, loneliness and housing tenure, was in accordance with
established literature, supporting the use of the data to study the
relationships between exposures and outcomes. Previous work on
health surveys with selection bias because of non-participation,
including UK Biobank, have indicated that they can be used to
give estimates of association,14,32,35 although biased results may
occur in some cases.36,37 For example, the relative under-participa-
tion of unskilled workers in the MHQ (around one-fifth of the pro-
portion in the population) could mask an association with a variable
that was related to unskilled work.
Strengths and limitations
We developed a questionnaire through a consensus approach with
clear aims of capturing enough data to characterise participants as
having a lifetime history of depression and other phenotypes.
Validated instruments were used where possible. The consortium
working on the questionnaire included mental health researchers
and members of the UK Biobank team working in collaboration
to develop the optimum approach. The derived variables of likely
categorical diagnoses will be added to the UK Biobank resource,
facilitating those less familiar with mental health to use the results
Table 3 Selected personal characteristics, socioeconomic factors, risk factors and health behaviours by status for likely lifetime occurrence of oper-
ationally defined syndromes (people may be included in more than one category)
Characteristics
No ‘lifetime’
criteria meta
(n = 108 752)
Depressionb
(n = 37 434)
Bipolar
type 1c
(n = 931)
Anxiety
disorder
(GAD)b
(n = 11 111)
Unusual
experiencesd
(n = 7803)
Addictione
(n = 9386)
Personal characteristics
Age,f n (%) 45–54 14 364 (13) 7145 (19) 228 (24) 2348 (21) 1485 (19) 2013 (21)
55–64 33 307 (31) 14 809 (40) 417 (45) 4470 (40) 2904 (37) 3428 (37)
65–74 51 705 (48) 13 739 (37) 261 (28) 3892 (35) 2960 (38) 3466 (37)
≥75 (oldest is 82) 9376 (9) 1741 (5) 25 (3) 401 (4) 454 (6) 479 (5)
Gender, n (%) Female 57 556 (53) 25 815 (69) 532 (57) 7404 (67) 4718 (60) 4556 (49)
Ethnicity, n (%) White 105 072 (97) 36 297 (97) 892 (96) 10 749 (97) 7503 (96) 9037 (96)
Townsend Deprivation Score,g
n (%)
Most deprived (TDS ≥2) 11 783 (11) 5656 (15) 201 (22) 1856 (17) 1426 (18) 1941 (21)
Highest qualification, n (%) Degree 48 700 (45) 16 939 (45) 425 (46) 5071 (46) 3646 (47) 4531 (48)
Housing tenure, n (%) Renth 4162 (4) 2906 (8) 155 (17) 1026 (9) 854 (11) 1109 (12)
Known risk factors
Neuroticism score,i mean (s.d.) 3.2 (2.8) 5.6 (3.3) 3.8 (3.1) 7.1 (3.3) 5.2 (3.5) 5.4 (3.5)
Adverse life experiences, n (%) Childhood screenj 43 913 (40) 21 144 (56) 638 (69) 6931 (62) 4783 (61) 5800 (62)
Adult screenk 50 226 (46) 23 893 (64) 685 (74) 7581 (68) 5284 (68) 6303 (67)
Trauma exposurel 50 771 (47) 22 166 (59) 665 (71) 6877 (62) 5439 (70) 6278 (67)
Social connection, n (%) Lonelinessi,m 2976 (3) 2367 (6) 94 (10) 971 (9) 570 (7) 669 (7)
Social isolationi 7793 (7) 3827 (10) 126 (14) 1173 (11) 931 (12) 1200 (13)
Illness Longstanding illness,
disability or infirmityi
26 341 (24) 13 363 (36) 503 (54) 4581 (41) 3242 (42) 3588 (38)
Health behaviours
Smoking status,i n (%) Current 6235 (6) 3638 (10) 158 (17) 1194 (11) 837 (11) 1916 (20)
Cannabis use (lifetime), n (%) Daily 868 (1) 914 (2) 63 (7) 346 (3) 258 (3) 867 (9)
Physical activity,i n (%) Moderate activity ≥ three times
a week
39 677 (36) 13 988 (37) 345 (37) 4174 (38) 2846 (36) 3602 (38)
a. Criteria not met for depression, generalised anxiety disorder (GAD), unusual experiences or addiction.
b. Criteria met for disorder on Composite International Diagnostic Interview Short Form (CIDI-SF) lifetime.
c. Criteria met for both lifetime depression and lifetime mania.
d. Reported potential hallucination or delusion at any point in their life.
e. Positively endorsed: ‘Have you been addicted to or dependent on one or more things, including substances (not cigarettes/coffee) or behaviours (such as gambling)?’.
f. Age when mental health questionnaire completed, derived from date of birth.
g. Townsend Material Deprivation Score is based on postcode areas.
h. Includes rent social and rent private, excludes other categories of housing tenure.
i. From baseline assessment 2006–2010
j. Criteria met for possible abuse or neglect on Childhood Trauma Screener.
k. Criteria met for adverse situations as an adult: lack of confiding relationship, abusive relationships and money problems.
l. Reports one or more of six situations that are known to be triggers for trauma-related disorders.
m. There is some overlap between the adult screen and loneliness screen, which both ask about confiding relationships: adult screen includes lack of confiding relationship over the adult
lifetime; loneliness includes lack of confiding relationship at the time of baseline assessment.
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efficiently. The UK Biobank data, including that from the MHQ, is
available to researchers and we have made the code used to derive
the results in this paper freely available, allowing other researchers
both to query our findings and build upon them for their own work.
The ‘healthy volunteer’ effect may limit applications of the data.
The questionnaire was also heavily reliant on participant report,
which may be affected by the stigma of reporting psychiatric symp-
toms, and tends to underestimate lifetime prevalence through
forgetting or re-evaluating distant events.14,28,38 This caveat on ‘life-
time’ disorder is another reason this data is more suitable for asso-
ciation studies than prevalence estimates. Researchers considering
the use of UK Biobank data will need to assess the likely impact
of selection bias and recall bias on a case-by-case basis, as this will
affect whether UK Biobank is suitable and the choice of mental
health data within UK Biobank.39
As a result of restrictions of time and space, the questionnaire
was limited in the topics it could cover. The focus of the question-
naire was on categorical diagnoses rather than dimensional traits,
which will tend to confirm conventional ICD/DSM nosology of psy-
chiatric disorder and may not suit some research.40 In particular,
tools were chosen that are based on DSM-IV disorders, which
reflects current practise (for example National Institute for Health
and Care Excellence guidelines on depression and anxiety use
DSM-IV definitions).41,42 Of the disorders with operational classifi-
cation, all would generalise to DSM-5, except PTSD,43 and the
concepts are valid for ICD-10 disorders, although the threshold of
disorder may be different, for example depression is diagnosed
with fewer symptoms in DSM than ICD.41 Developments in UK
Biobank such as primary care linkage and proposed future question-
naires (such as quality of life, activities of daily living) will continue
to enrich the picture of mental health in the cohort going forward.
Implications
In conclusion, UK Biobank offers a unique opportunity to research
common disorders in a well-characterised longitudinal cohort of
UK adults. A detailed MHQ has now been completed by 157 366
participants, including self-report, operationally defined lifetime
disorder status and detailed phenotype information on mood dis-
order. The proportion of participants with mental disorders and
the patterns of participants experiencing symptoms and disorders
was as expected despite a ‘healthy volunteer’ selection bias.
Further work on mental health phenotyping for UK Biobank
includes validation of Hospital Episode Statistics for mental
health diagnoses,15 incorporation of general practice records, tri-
angulation of health record and questionnaire data,39 and investiga-
tion of further putative phenotypes.44 Existing projects utilising UK
Biobank mental health data can be seen in a searchable database of
approved research (http://www.ukbiobank.ac.uk/approved-
research/).
This study also demonstrates the substantial burden of mental
health disorders, including potentially dangerous patterns of
alcohol consumption. Given the known impact of mental health
on physical health, mental health data and its associations should
interest researchers from every biomedical speciality. This study
suggests that UK Biobank could be a powerful tool for such
studies, and as it is open to all bona fide health researchers for
work in the public good, we hope this study will inspire both existing
and new users of UK Biobank.
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